Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


28.01.2019

1 Br J Cancer
1 Cancer Chemother Pharmacol
1 Cancer Lett
1 Clin Cancer Res
5 Gynecol Oncol
1 Int J Cancer
3 Int J Gynecol Pathol
1 Oncol Rep
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Cancer

  1. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  2. ISHIKAWA M, Kawai M, Maeda T, Kagawa Y, et al
    Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic.
    Cancer Chemother Pharmacol. 2018;81:399-411.
    PubMed     Text format     Abstract available


    Cancer Lett

  3. HAN W, Zhang Y, Niu C, Guo J, et al
    BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.
    Cancer Lett. 2019;445:45-56.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  4. GREENWOOD HE, McCormick PN, Gendron T, Glaser M, et al
    Measurement of tumor antioxidant capacity and prediction of chemotherapy resistance in preclinical models of ovarian cancer by positron emission tomography.
    Clin Cancer Res. 2019 Jan 16. pii: 1078-0432.CCR-18-3423.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  5. MONK BJ, Kauderer JT, Moxley KM, Bonebrake AJ, et al
    A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31281.
    PubMed     Text format     Abstract available

  6. CARTER NJ, Marshall ML, Susswein LR, Zorn KK, et al
    Germline pathogenic variants identified in women with ovarian tumors.
    Gynecol Oncol. 2018 Oct 12. pii: S0090-8258(18)31249.
    PubMed     Text format     Abstract available

  7. TA RM, Hecht JL, Lin DI
    Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Gynecol Oncol. 2018 Oct 16. pii: S0090-8258(18)31291.
    PubMed     Text format     Abstract available

  8. DING J, Cheng XY, Liu S, Ji HY, et al
    Apatinib exerts anti-tumour effects on ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30043.
    PubMed     Text format     Abstract available

  9. UPPENDAHL LD, Felices M, Bendzick L, Ryan C, et al
    Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 15. pii: S0090-8258(19)30039.
    PubMed     Text format     Abstract available


    Int J Cancer

  10. PAPAEVANGELOU E, Almeida GS, Box C, deSouza NM, et al
    The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31392.
    PubMed     Text format     Abstract available


    Int J Gynecol Pathol

  11. LEE PJ, McNulty S, Duncavage EJ, Heusel JW, et al
    Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
    Int J Gynecol Pathol. 2018;37:581-589.
    PubMed     Text format     Abstract available

  12. BENNETT JA, Young RH, Chuang AY, Lerwill MF, et al
    Ovarian Metastases of Breast Cancers With Signet Ring Cells: A Report of 17 Cases Including 14 Krukenberg Tumors.
    Int J Gynecol Pathol. 2018;37:507-515.
    PubMed     Text format     Abstract available

  13. HAZAMA Y, Moriya T, Sugihara M, Sano R, et al
    The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
    Int J Gynecol Pathol. 2018;37:516-524.
    PubMed     Text format     Abstract available


    Oncol Rep

  14. WANG D, Xu Y, Feng L, Yin P, et al
    RGS5 decreases the proliferation of human ovarian carcinomaderived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.
    Oncol Rep. 2019;41:165-177.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  15. ZHAO Y, Cao J, Melamed A, Worley M, et al
    Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
    Proc Natl Acad Sci U S A. 2019 Jan 18. pii: 1818357116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: